↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension

Overview of attention for article published in Integrated Blood Pressure Control, January 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
14 Mendeley
Title
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
Published in
Integrated Blood Pressure Control, January 2016
DOI 10.2147/ibpc.s68230
Pubmed ID
Authors

Todd Bull, Steven Pugliese

Abstract

The development of parenteral prostacyclin therapy marked a dramatic breakthrough in the treatment of pulmonary arterial hypertension (PAH). Intravenous (IV) epoprostenol was the first PAH specific therapy and to date, remains the only treatment to demonstrate a mortality benefit. Because of the inherent complexities and risks of treating patients with continuous infusion IV therapy, there is great interest in the development of an oral prostacyclin analog that could mimic the benefits of IV therapy. Herein, we highlight the development of oral prostacyclin therapy, focusing on oral treprostinil, the only US Food and Drug Administration approved oral prostacyclin. Recent Phase III clinical trials have shown the drug to improve exercise tolerance in treatment-naïve PAH patients, but not patients on background oral therapy. Oral treprostinil appears to be most efficacious at higher doses, but its side effect profile and complexities with dosing complicate its use. While oral treprostinil's current therapeutic role in PAH remains unclear, ongoing studies of this class of medication should help clarify their role in the treatment of PAH.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 7%
Unknown 13 93%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 2 14%
Researcher 2 14%
Unspecified 1 7%
Other 1 7%
Student > Bachelor 1 7%
Other 3 21%
Unknown 4 29%
Readers by discipline Count As %
Medicine and Dentistry 4 29%
Agricultural and Biological Sciences 2 14%
Unspecified 2 14%
Psychology 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Other 0 0%
Unknown 4 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2016.
All research outputs
#3,511,028
of 7,054,473 outputs
Outputs from Integrated Blood Pressure Control
#14
of 27 outputs
Outputs of similar age
#165,920
of 318,380 outputs
Outputs of similar age from Integrated Blood Pressure Control
#3
of 5 outputs
Altmetric has tracked 7,054,473 research outputs across all sources so far. This one is in the 28th percentile – i.e., 28% of other outputs scored the same or lower than it.
So far Altmetric has tracked 27 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one scored the same or higher as 13 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,380 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.